Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Gregory Y. H. Lip
This Meet the Expert session was chaired by G.Y.H. Lip (Birmingham, GB) and L. Friberg (Stockholm, SE), accompanied by expert panellists, Dr F Marin (Spain), Dr L H Rasmussen (Denmark) and Dr A Bollmann (Germany). Dr Marin presented a case of the 74 year old man with peripheral artery disease - how to assess risks of stroke, bleeding and falls. This led to lively discussion on the importance of the CHA2DS2-VASc score over CHADS2, as well as the independent additive effect of peripheral artery disease to the predictive value of the CHADS2 score . Bleeding risk is assessed by the HAS-BLED score, and has been well-validated in recent studies, even being superior to other scores (including the ATRIA score) [2,3,4]. Dr Bollmann discussed a case of the young female patient undergoing AF ablation - should we anticoagulate? Recent studies have shown that female patients overall have an increased risk of stroke in AF, but there is an age effect [5,6]. If a female patient fulfils the criteria of ‘age <65 and lone AF’ their risk of stroke is so low, that antithrombotic therapy is not recommended. The recent joint guidelines following ablation therapy were discussed . Prof Lip closed the session with a presentation on ‘What do the Guidelines say?’ with particular reference to the new 2012 focused update guidelines on AF management , published and presented at this meeting. The important point in this guideline is the practice shift towards identification of ‘truly low risk’ patients with AF who do not need any antithrombotic therapy, whilst those with one or more stroke risk factors can be offered effective stroke prevention, which is oral anticoagulation therapy whether with well controlled warfarin (INR 2-3) or one of the novel anticoagulant drugs.
REFERENCES 1. Olesen J et al Am J Med 2012 August 2. Apostolakis S et al. J Am Coll Cardiol 2012 August 3. Roldan V et al Chest 2012 4. Lip GYH et al Circulation Arrhythmias and Electrophysiology 2012 5. Friberg L et al BMJ 2012 6. Olesen et al Chest 2011 7. Calkins H et al 2012 8. Camm AJ et al Eur Heart J 2012
Anti-thrombotic therapy in atrial fibrillation - difficult management scenarios
© 2017 European Society of Cardiology. All rights reserved